{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T14:28:19Z","timestamp":1782570499121,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"DOI":"10.1186\/s12959-024-00652-1","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T09:17:06Z","timestamp":1730107026000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Correlation between a 2-week change in platelet count and clinical outcomes after the initiation of ravulizumab treatment in adult patients with atypical hemolytic uremic syndrome: post-hoc analysis of the phase III trial"],"prefix":"10.1186","volume":"22","author":[{"given":"Masanori","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Shimono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yokosawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"652_CR1","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/s0140-6736(17)30062-4","volume":"390","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Zuber J, Fr\u00e9meaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;390:681\u201396. https:\/\/doi.org\/10.1016\/s0140-6736(17)30062-4.","journal-title":"Lancet"},{"key":"652_CR2","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/s0140-6736(22)01202-8","volume":"400","author":"M Michael","year":"2022","unstructured":"Michael M, Bagga A, Sartain SE, Smith RJH. Haemolytic uraemic syndrome. Lancet. 2022;400:1722\u201340. https:\/\/doi.org\/10.1016\/s0140-6736(22)01202-8.","journal-title":"Lancet"},{"key":"652_CR3","first-page":"2","volume":"14 Suppl 11","author":"J Laurence","year":"2016","unstructured":"Laurence J, Haller H, Mannucci PM, Nangaku M, Praga M, Rodriguez de Cordoba S. Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clin Adv Hematol Oncol. 2016;14 Suppl 11:2\u201315.","journal-title":"Clin Adv Hematol Oncol"},{"key":"652_CR4","doi-asserted-by":"publisher","first-page":"205435812110087","DOI":"10.1177\/20543581211008707","volume":"8","author":"PA McFarlane","year":"2021","unstructured":"McFarlane PA, Bitzan M, Broome C, Baran D, Garland J, Girard LP, Grewal K, Lapeyraque AL, Patriquin CJ, Pavenski K, Licht C. Making the correct diagnosis in thrombotic microangiopathy: a narrative review. Can J Kidney Health Dis. 2021;8:20543581211008708. https:\/\/doi.org\/10.1177\/20543581211008707.","journal-title":"Can J Kidney Health Dis"},{"key":"652_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/1744-9987.12763","volume":"23","author":"R Raina","year":"2019","unstructured":"Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, Bagga A. Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Ther Apher Dial. 2019;23:4\u201321. https:\/\/doi.org\/10.1111\/1744-9987.12763.","journal-title":"Ther Apher Dial"},{"key":"652_CR6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.thromres.2015.09.007","volume":"136","author":"PM Mannucci","year":"2015","unstructured":"Mannucci PM, Cugno M. The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: laboratory weapons and their impact on treatment choice and monitoring. Thromb Res. 2015;136:851\u20134. https:\/\/doi.org\/10.1016\/j.thromres.2015.09.007.","journal-title":"Thromb Res"},{"key":"652_CR7","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","volume":"91","author":"TH Goodship","year":"2017","unstructured":"Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fr\u00e9meaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodr\u00edguez de C\u00f3rdoba S, Roumenina LT, Sethi S, Smith RJ. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference. Kidney Int. 2017;91:539\u201351. https:\/\/doi.org\/10.1016\/j.kint.2016.10.005.","journal-title":"Kidney Int."},{"key":"652_CR8","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1182\/blood-2014-09-600411","volume":"125","author":"R Cofiell","year":"2015","unstructured":"Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, Bedrosian CL, Faas SJ. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood. 2015;125:3253\u201362. https:\/\/doi.org\/10.1182\/blood-2014-09-600411.","journal-title":"Blood"},{"key":"652_CR9","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, N\u00fcrnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169\u201381. https:\/\/doi.org\/10.1056\/NEJMoa1208981.","journal-title":"N Engl J Med"},{"key":"652_CR10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","volume":"89","author":"LA Greenbaum","year":"2016","unstructured":"Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016;89:701\u201311. https:\/\/doi.org\/10.1016\/j.kint.2015.11.026.","journal-title":"Kidney Int"},{"key":"652_CR11","doi-asserted-by":"publisher","unstructured":"Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87:1061\u201373. https:\/\/doi.org\/10.1038\/ki.2014.423.","DOI":"10.1038\/ki.2014.423"},{"key":"652_CR12","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/ndt\/gfac150","volume":"38","author":"S Ito","year":"2023","unstructured":"Ito S, Hataya H, Ashida A, Hamada R, Ishikawa T, Ishikawa Y, Shimono A, Konomoto T, Miyazawa T, Ogura M, Tanaka K, Kagami S. Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan. Nephrol Dial Transplant. 2023;38:414\u201324. https:\/\/doi.org\/10.1093\/ndt\/gfac150.","journal-title":"Nephrol Dial Transplant"},{"key":"652_CR13","doi-asserted-by":"publisher","unstructured":"Maruyama S, Ikeda Y, Kaname S, Kato N, Matsumoto M, Ishikawa Y, Shimono A, Miyakawa Y, Nangaku M, Shibagaki Y, Okada H. Eculizumab for adult patients with atypical haemolytic-uraemic syndrome: full dataset analysis of Japanese post-marketing surveillance. J Nephrol. 2024; in press. https:\/\/doi.org\/10.1007\/s40620-024-01921-y.","DOI":"10.1007\/s40620-024-01921-y"},{"key":"652_CR14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s12185-023-03630-x","volume":"118","author":"JI Nishimura","year":"2023","unstructured":"Nishimura JI, Kawaguchi T, Ito S, Murai H, Shimono A, Matsuda T, Fukamizu Y, Akiyama H, Hayashi H, Nakano T, Maruyama S. Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan. Int J Hematol. 2023;118:419\u201331. https:\/\/doi.org\/10.1007\/s12185-023-03630-x.","journal-title":"Int J Hematol"},{"key":"652_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/bjh.15790","volume":"185","author":"G Soci\u00e9","year":"2019","unstructured":"Soci\u00e9 G, Caby-Tosi MP, Marantz JL, Cole A, Bedrosian CL, Gasteyger C, Mujeebuddin A, Hillmen P, Vande Walle J, Haller H. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol. 2019;185:297\u2013310. https:\/\/doi.org\/10.1111\/bjh.15790.","journal-title":"Br J Haematol"},{"key":"652_CR16","doi-asserted-by":"publisher","unstructured":"Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H. The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment. Kidney Int. 2020;97:1287\u201396. https:\/\/doi.org\/10.1016\/j.kint.2020.01.035. Erratum: Kidney Int. 2020;98:1621. https:\/\/doi.org\/10.1016\/j.kint.2020.11.001. Corrigendum: Kidney Int. 2021;99:1244. https:\/\/doi.org\/10.1016\/j.kint.2021.03.008.","DOI":"10.1016\/j.kint.2020.01.035 10.1016\/j.kint.2020.11.001 10.1016\/j.kint.2021.03.008"},{"key":"652_CR17","unstructured":"Ultomiris package insert. Available from: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/870056_6399427A2023_1_01."},{"key":"652_CR18","doi-asserted-by":"publisher","unstructured":"Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment. Kidney Int. 2021;100:225\u201337. https:\/\/doi.org\/10.1016\/j.kint.2020.10.046. Corrigendum: Kidney Int. 2023;104:205. https:\/\/doi.org\/10.1016\/j.kint.2023.04.010.","DOI":"10.1016\/j.kint.2020.10.046 10.1016\/j.kint.2023.04.010"},{"key":"652_CR19","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.ekir.2021.03.884","volume":"6","author":"T Barbour","year":"2021","unstructured":"Barbour T, Scully M, Ariceta G, Cataland S, Garlo K, Heyne N, Luque Y, Menne J, Miyakawa Y, Yoon SS, Kavanagh D. Long-term efficacy and safety of the long-acting complement C5 inhibitor ravulizumab for the treatment of atypical hemolytic uremic syndrome in adults. Kidney Int Rep. 2021;6:1603\u201313. https:\/\/doi.org\/10.1016\/j.ekir.2021.03.884.","journal-title":"Kidney Int Rep"},{"key":"652_CR20","doi-asserted-by":"publisher","unstructured":"Dixon PB, Kavanagh D, Aris MDA, Adams B, Kang GH, Wang E, Garlo K, Ogawa M, Chakravarty SAP, Heyne N, Kim HS, Cataland S, Yoon SS, Miyakawa Y, Luque Y, Muff-Luett M, Tanaka K, Greenbaum AL. Ravulizumab in atypical hemolytic uremic syndrome: an analysis of 2-year efficacy and safety outcomes in 2 phase 3 trials. Kidney Med. 2024; in press. https:\/\/doi.org\/10.1016\/j.xkme.2024.100855.","DOI":"10.1016\/j.xkme.2024.100855"},{"key":"652_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40620-016-0288-3","volume":"30","author":"JV Walle","year":"2017","unstructured":"Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol. 2017;30:127\u201334. https:\/\/doi.org\/10.1007\/s40620-016-0288-3.","journal-title":"J Nephrol"},{"key":"652_CR22","first-page":"34","volume":"7","author":"A Dorgalaleh","year":"2013","unstructured":"Dorgalaleh A, Mahmudi M, Tabibian S, Khatib ZK, Tamaddon GH, Moghaddam ES, Bamedi T, Alizadeh S, Moradi E. Anemia and thrombocytopenia in acute and chronic renal failure. Int J Hematol Oncol Stem Cell Res. 2013;7:34\u20139.","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"652_CR23","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/ki.2012.130","volume":"82","author":"JT Daugirdas","year":"2012","unstructured":"Daugirdas JT, Bernardo AA. Hemodialysis effect on platelet count and function and hemodialysis-associated thrombocytopenia. Kidney Int. 2012;82:147\u201357. https:\/\/doi.org\/10.1038\/ki.2012.130.","journal-title":"Kidney Int"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-024-00652-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-024-00652-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-024-00652-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T20:04:04Z","timestamp":1730145844000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/s12959-024-00652-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["652"],"URL":"https:\/\/doi.org\/10.1186\/s12959-024-00652-1","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"9 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ALXN1210-aHUS-311 phase III study protocol was approved by the Institutional Review Board or Independent Ethics Committee at each participating center, and the study was conducted in accordance with the Declaration of Helsinki and the Council for International Organizations of Medical Sciences International Ethical Guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from the individual participants for the original study. The current study reports a post-hoc analysis and additional consent was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M. Matsumoto received research funding and honoraria for lectures and participation on an\u00a0advisory board from Alexion Pharma GK. A. Shimono, J. Yokosawa, and K. Hirose are employees of Alexion Pharma GK and shareholders of AstraZeneca. E. Wang is an employee of\u00a0Alexion, AstraZeneca Rare Disease, and a shareholder of AstraZeneca. S. Maruyama received research funding and honoraria for lectures and participation on an\u00a0advisory board from Alexion Pharma GK.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"93"}}